ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: FR-PO335

Influence of Sex and Other Risk Factors, Including Kidney Function, on Myocardial Microvascular Function in Individuals with Type 2 Diabetes Free of Overt Cardiovascular Disease: The DiaHeart Study

Session Information

Category: Diabetic Kidney Disease

  • 702 Diabetic Kidney Disease: Clinical

Authors

  • Skriver-Møller, Anne-Cathrine, Steno Diabetes Center Copenhagen, Herlev, Capital Region of Denmark, Denmark
  • Hasbak, Philip, Rigshospitalet, Kobenhavn, Denmark
  • Rasmussen, Ida Kirstine Bull, Steno Diabetes Center Copenhagen, Herlev, Capital Region of Denmark, Denmark
  • Blond, Martin Bæk, Steno Diabetes Center Copenhagen, Herlev, Capital Region of Denmark, Denmark
  • Wasehuus, Victor, Steno Diabetes Center Copenhagen, Herlev, Capital Region of Denmark, Denmark
  • Lassen, Mats H., Gentofte Hospital, Hellerup, Hovedstaden, Denmark
  • Lindhardt, Morten, Zealand University Hospital Holbaek, Holbaek, Denmark
  • Kofoed-Enevoldsen, Allan, Nykobing F Sygehus, Nykobing, Region Sjælland, Denmark
  • Kielgast, Urd Lynge, Sjaellands Universitetshospital Koge, Koge, Sjælland, Denmark
  • Zobel, Emilie, Steno Diabetes Center Copenhagen, Herlev, Capital Region of Denmark, Denmark
  • Holmvang, Lene, Rigshospitalet, Kobenhavn, Denmark
  • Rossing, Peter, Steno Diabetes Center Copenhagen, Herlev, Capital Region of Denmark, Denmark
  • Biering-Sørensen, Tor, Steno Diabetes Center Copenhagen, Herlev, Capital Region of Denmark, Denmark
  • Ripa, Rasmus S., Rigshospitalet, Kobenhavn, Denmark
  • Kjaer, Andreas, Rigshospitalet, Kobenhavn, Denmark
  • Hansen, Tine, Steno Diabetes Center Copenhagen, Herlev, Capital Region of Denmark, Denmark
Background

Type 2 diabetes (T2D) is a stronger risk factor for cardiovascular disease (CVD) in women than in men and increased with progressive CKD. This might in part be due to women being more susceptible to developing myocardial microvascular dysfunction when compared with men with a similar risk profile. The myocardial flow reserve (MFR) represents the function of the epicardial arteries and the microvasculature and can be measured with a cardiac (Rb82)-PET/CT. We investigated the presence of sex dependent differential effects of CV risk factors, including kidney function, on MFR in people with T2D, free of overt CVD.

Methods

Cross-sectional analysis of a prospective study including 901 T2D individuals. All underwent a cardiac 82Rb-PET/CT for estimation of MFR. Associations between MFR and other risk factors were assessed using linear regression. Differential effects of risk factors by sex were assessed by including an interaction term between one risk factor and sex at a time.

Results

Mean (SD) age was 65 (9) years and 266 (30%) were women. Mean eGFR was 82.1 (21.8) ml/min/1.732 and median (IQR) UACR 7.7 (4.9-19.9) mg/g. MFR was lower in women than in men (2.44 (0.61) vs. 2.59 (0.77), p=0.003). MFR was lower with increasing degree of albuminuria; 2.61 (0.73) for normal, 2.35 (0.67) for moderately and 2.11 (0.72) for severely increased albuminuria, p<0.001.
In a model including age, sex, diabetes duration, BMI, smoking, systolic blood pressure, logUACR, eGFR, HbA1c, and LDL-cholesterol MFR was negatively associated with female sex β -0.19 (95%CI -0.29 to -0.09, p<0.001), age -0.19 (-0.25 to -0.13, p<0.001), and logUACR -0.09 (-0.13 to -0.05, p<0.001). There were no statistically significant interactions with sex for any of the risk factors.

Conclusion

In individuals with T2D free of overt CVD, MFR was lower in women than in men and lower with higher level of albuminuria. Despite lower MFR in women, we found no indications of sex dependent differential effects of any risk factors including UACR and eGFR on MFR.

Funding

  • Commercial Support – Novo Nordisk Foundation